Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Siglec-G represses DAMP-mediated effects on T cells
Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy
Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy
View: Text | PDF
Research Article Immunology Transplantation

Siglec-G represses DAMP-mediated effects on T cells

  • Text
  • PDF
Abstract

The role of negative regulators or suppressors of the damage-associated molecular pattern–mediated (DAMP-mediated) stimulation of innate immune responses is being increasingly appreciated. However, the presence and function of suppressors of DAMP-mediated effects on T cells, and whether they can be targeted to mitigate T cell–dependent immunopathology remain unknown. Sialic acid–binding immunoglobulin-like lectin G (Siglec-G) is a negative regulator of DAMP-mediated responses in innate immune cells, but its T cell–autonomous role is unknown. Utilizing loss-of-function–based (genetic knockout) and gain-of-function–based (agonist) approaches, we demonstrate that in the presence of certain DAMPs, Siglec-G suppressed in vitro and in vivo T cell responses. We also demonstrate that its T cell–autonomous role is critical for modulating the severity of the T cell–mediated immunopathology, graft-versus-host disease (GVHD). Enhancing the Siglec-G signaling in donor T cells with its agonist, a CD24Fc fusion protein, ameliorated GVHD while preserving sufficient graft-versus-tumor (GVT) effects in vivo. Collectively, these data demonstrate that Siglec-G is a potentially novel negative regulator of T cell responses, which can be targeted to mitigate GVHD.

Authors

Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Cynthia Zajac, Chen Liu, Thomas Braun, Hideaki Fujiwara, Julia Wu, Yaping Sun, Stuart Brabbs, Hiroya Tamaki, John Magenau, Pang Zheng, Yang Liu, Pavan Reddy

×

Figure 6

Effect of enhancing Siglec-G responses with CD24Fc on graft-versus-tumor (GVT) responses.

Options: View larger image (or click on image) Download as PowerPoint
Effect of enhancing Siglec-G responses with CD24Fc on graft-versus-tumor...
BALB/c animals were lethally irradiated with 8.5 Gy and infused with 0.75 × 106 CD90+ T cells along with 5 × 106 T cell–depleted bone marrow (TCD-BM) cells from either syngeneic BALB/c or allogeneic MHC-mismatched B6 donors concurrently with syngeneic 1 × 102 P815 tumors simultaneously with allogeneic hematopoietic cell transplantation (allo-HCT). The recipients were injected with CD24Fc or diluent control on day 0 before allogeneic bone marrow transplantation (allo-BMT). (A) Overall survival. Kaplan-Meier method, **P < 0.01 when control diluent versus CD24Fc treatment animals were compared. (B) Tumor-related mortality. n = 7–21 per group, pooled from 3 experiments. (C) Tumor growth was monitored using bioluminescence imaging (BLI) at day 14 after allo-HCT (n = 2–5). Representative data from 3 independent experiments are shown. (D) Tumor-related mortality data of P815, 5 × 102/mouse (n = 3–8 per group), pooled from 2 experiments. (E) Tumor-related mortality of A20, 1 × 105/mouse. n = 4–11 per group, pooled from 2 experiments. (F) 51Cr-release assay using donor CD8+ T cells at day 14 after allo-HCT against MBL-2 (syngeneic) and P815 (allogeneic) tumors. Representative data from 3 independent experiments are shown. Data are shown as the mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts